beta
Trial Radar IA
Lo studio clinico NCT06768827 (NMoO) per Obesity and Overweight, Resistenza all'insulina, Obesity and Obesity-related Medical Conditions è non ancora in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede

New Mechanisms of Obesity (NMoO)

Non ancora in arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT06768827 (NMoO) è uno studio interventistico per Obesity and Overweight, Resistenza all'insulina, Obesity and Obesity-related Medical Conditions, attualmente non ancora in arruolamento. L'arruolamento dovrebbe iniziare il 1 novembre 2025, con l'obiettivo di raggiungere 55 partecipanti. Sotto la guida di l'Università di Yale, dovrebbe concludersi entro il 31 marzo 2030. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 26 settembre 2025.
Sommario breve
Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in youth with obesity.
Descrizione dettagliata
Pediatric obesity is a major health burden affecting millions of children and adolescents as it predisposes to the development of cardio-metabolic diseases early in life, such as insulin resistance, fatty liver disease and type 2 diabetes. Investigators have recently completed a series of studies to understand the relationship between the intestinal microbial activity and human metabolism in youth. It was observed that intestinal fermentation, a process through which fermentable carbohydrates are processed by intestinal bacteria, results in a variety of biological responses aimed at protecting the human body from developing obesity and some of its metabolic complications, such as insulin resistance and ectopic fat accumulation. In particular, investigators observed that intestinal fermentation causes 1- a reduction of plasma free fatty acids (FFA), due to the inhibition of adipose tissue lipolysis (ATL); 2- a marked entero-endocrine response to reduce appetite, characterized by an increase in the production of peptide YY (PYY) and glucagon-like peptide1 (GLP-1) and a reduced production of ghrelin. In addition, investigators observed that some intestinal fermentation responses are impaired in youth with obesity and insulin resistance (OIR). In light of this evidence, the current proposal will address: 1- how adipose tissue lipolysis response to intestinal fermentation is affected by insulin resistance; 2- whether changes in ATL, observed when fermentation occurs, are also associated with a reduction of glycerol derived neo-gluconeogenesis; 3- if physical activity may restore the entero-endocrine and adipose tissue response to intestinal fermentation in youth with insulin resistance. This is the first study to test the effect of insulin resistance on the relationship between intestinal microbial metabolic activity and human metabolism (namely adipose tissue lipolysis, gluconeogenesis and entero-endocrine response). The results obtained will provide fundamental insight into how insulin resistance occurring in youth with obesity affects the metabolic response to fermentable carbohydrates. In fact, despite the large body of literature showing an association between intestinal microbial fermentation and human metabolism, how and whether insulin resistance may modulate this association remains unknown.
Titolo ufficiale

Pathogenic Mechanisms of Obesity and Its Cardiometabolic Complications

Condizioni
Obesity and OverweightResistenza all'insulinaObesity and Obesity-related Medical Conditions
Altri ID dello studio
Numero NCT
Data di inizio (effettiva)
2025-11
Ultimo aggiornamento pubblicato
2025-09-26
Data di completamento (stimata)
2030-03-31
Arruolamento (previsto)
55
Tipo di studio
Interventistico
FASE
N.D.
Stato
Non ancora in arruolamento
Parole chiave
Obesity
Youth
Insulin Resistance
Intestinal Fermentation
Scopo principale
Ricerca di base
Allocazione
Randomizzato
Modello di intervento
In parallelo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
SperimentaleRemote physical exercise
Lactulose Oral Product
Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
Comparatore attivoControl physical excercise
Lactulose Oral Product
Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL)
Changes in adipose tissue lipolysis occurring after colonic fermentation (stimulated by lactulose) will be compared between youth with obesity and insulin resistance (OIR) and with obesity and without insulin resistance (OIS). Lipolysis will be measured by using change in D5-glycerol concentration.
6 hours
CHANGES IN GLUCONEOGENESIS
Gluconeogenesis (GLC) will be measured using change in deuterium oxide concentration after colonic fermentation due to lactulose ingestion and compared between OIS and OIR.
6 hours
CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL)
Changes in ATL due to colonic fermentation will be measured in two groups of OIR youth. One group will undergo physical activity for 12 weeks and another group will undergo a control intervention. Lipolysis will be measured by using change in D5-glycerol concentration.
Baseline and 12 weeks
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
CHANGES IN PEPTIDE YY (PYY) concentration
Changes in PYY concentration after lactulose intervention will be compared between OIS and OIR.
Baseline and 12 weeks
CHANGES IN GHRELIN concentration
Changes in GHRELIN concentration after lactulose intervention will be compared between OIS and OIR.
Baseline and 12 weeks
Criteri di eleggibilità

Età idonea
Bambino, Adulto
Età minima
15 Years
Sessi idonei
Tutti
  • Age 15 to 22 years
  • In puberty (girls and boys: Tanner stage III-V);
  • BMI >85th

  • Pregnancy;
  • endocrinopathies (e.g., Cushing syndrome);
  • substance abuse;
  • medications affecting insulin resistance such as metformin, GLP-1 analogues; -
  • high fibers intake (> 30g/day) as assessed by a 3-day food record.
  • National Institutes of Health (NIH) logoNational Institutes of Health (NIH)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) logoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contatti principali dello studio
Contatto: NICOLA SANTORO, MD, PhD, 2037852819, [email protected]
1 Centri dello studio in 1 paesi

Connecticut

Yale University, New Haven, Connecticut, 06520, United States